Skip to content
Home/Companies/Biotech/PipeBio

PipeBio

Biotech·Denmark·Exited 2024·Held 3yr
Entry
2021
Hold
3yr
Exit
2024

Who owns PipeBio?

PipeBio is a Danish Biotech company, now owned by Benchling, which acquired it in 2024 from byFounders.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
byFounders
Investor
byFounders
byFounders II · 2020 · VC

Key facts

HQDenmark
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Benchling
Exit Year
2024

More from byFounders II

Other portfolio companies in the same fund.

Aumio
Aumio
Active
HealthTechGermany· 2022
Cello
Cello
Active
SaaSGermany· 2022
Creative Force
Active
SaaSDenmark· 2022
Ento Labs
Active
ClimateTechDenmark· 2022
IXI
Active
MedTechFinland· 2022
Salto X
Active
FintechEstonia· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns PipeBio?

PipeBio is now owned by Benchling, which acquired it in 2024 from byFounders.

When did Benchling acquire PipeBio?

Benchling acquired PipeBio in 2024, buying from byFounders.

Who did PipeBio sell to?

byFounders sold PipeBio to Benchling in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue